Abstract
The approach of all ophthalmologists, diabetologists and general practitioners seeing patients with diabetic retinopathy should be that good control of blood glucose, blood pressure and plasma lipids are all essential components of modern medical management. The more recent data on the use of fenofibrate in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye studies is reviewed. In FIELD, fenofibrate (200 mg/day) reduced the requirements for laser therapy and prevented disease progression in patients with pre-existing diabetic retinopathy. In ACCORD Eye, fenofibrate (160 mg daily) with simvastatin resulted in a 40% reduction in the odds of retinopathy progressing over 4 years, compared with simvastatin alone. This occurred with an increase in HDL-cholesterol and a decrease in the serum triglyceride level in the fenofibrate group, as compared with the placebo group, and was independent of glycaemic control. We believe fenofibrate is effective in preventing progression of established diabetic retinopathy in type 2 diabetes and should be considered for patients with pre-proliferative diabetic retinopathy and/or diabetic maculopathy, particularly in those with macular oedema requiring laser.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Fong DS, Aiello AP, Ferris FL, Klein R . Diabetic retinopathy. Diabetes Care 2004; 27: 2540–2553.
Candrilli SD, Davis KL, Kan HJ, Lucero MA, Rousculp MD . Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy. J Diabetes Complications 2007; 21: 306–314.
Diabetes UK. Diabetes and blindness: a focus on action. A report from Diabetes UK. June 2005. Available from www.diabetes.org.uk.
Emanuele N, Sacks J, Klein R, Reda D, Anderson R, Duckworth W et al. Ethnicity, race and baseline retinopathy correlates in the Veterans Affairs Diabetes Trial. Diabetes Care 2005; 28: 1954–1958.
Harris PD, Klein R, Cowie CC, Rowland M, Byrd-Holt DD . Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? Diabetes Care 1998; 21: 1230–1235.
The Eye Disease Prevalence Research Group. The prevalence of diabetic retinopathy among adults of the United States. Arch Ophthalmol 2004; 122: 552–563.
Day C . The rising tide of type 2 diabetes. Br J Diabetes Vasc Dis 2001; 414: 813–820.
Brownlee M . Banting Lecture 2004. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2005; 54: 1615–1625.
Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142: 961–969.
Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology 1991; 98: 766–785.
The UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UKPDS 33. Lancet 1998; 352: 837–853.
The UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–713.
Wright AD, Dodson PM . Diabetic retinopathy and blockade of renin-angiotensin system: new data from the DIRECT study programme. Eye 2010; 24: 1–6.
Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular oedema. Ophthalmology 2010; 117: 1064–1077.
Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F et al. A prospective, randomised trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular oedema (BOLT study) 12 month data; report 2. Ophthalmology 2010; 117: 1078–1086.
The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe non-proliferative diabetic retinopathy. Initial results of the protein kinase C beta inhibitor retinopathy study (PKC-DRS) multicntre randomised clinical trial. Diabetes 2005; 54: 2188–2197.
Dodson PM, Galton DJ, Winder AF . Retinal vascular abnormalities in the hyperlipidemias. Trans Ophthalmol Soc UK 1981; 101: 17–21.
Orchard TJ, Dorman JS, Maser RE, Becker DJ, Ellis D, LaPorte RE et al. Factors associated with avoidance of severe complications after 25 yr of IDDMC. Pittsburgh Epidemiology of Diabetes Complications Study I. Diabetes Care 1990; 13: 741–747.
Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, Chew EY et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss. Early Treatment Diabetic Retinopathy Study Report 18. Invest Ophthalmol Vis Sci 1998; 39: 233–252.
Ucgun NI, Yildirim Z, Kilic N, Gursel E . The importance of serum lipids in exudative diabetic macular edema in type 2 diabetic patients. Ann NY Acad Sci 2007; 1100: 213–217.
Miljanovic B, Glynn RJ, Nathan DM, Manson JE, Schaumberg DA . A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes 2004; 53: 2883–2892.
Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D, Garvey WT et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004; 45: 910–918.
Dodson PM . Management of diabetic retinopathy: could lipid lowering be a worthwhile treatment modality? Eye 2009; 23: 997–1003.
Donaldson M, Dodson PM . Medical treatment of diabetic retinopathy. Eye 2003; 17: 550–562.
Colhoun HM, Bettridge DJ, Durrington PN, Hitman GA, Neil W, Andrew-Livingstone HA et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–696.
Dodson PM . Medical treatment for diabetic retinopathy: do the FIELD microvascular study results support a role for lipid lowering? Practical Diabetes Int 2008; 25 (2): 76–79.
Duncan LJP, Cullen JF, Ireland JT, Nolan J, Clarke BF, Oliver MF . A three-year trial of atromid therapy in exudative diabetic retinopathy. Diabetes 1968; 17: 458–467.
Harrold BP, Marmion VJ, Gough KR . A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes 1969; 18: 285–291.
Cullen JF, Town SM, Cambell CJ . Double-blind trial of Atromid-S in exudative diabetic retinopathy. Trans Ophthalmol Soc UK 1974; 94: 554–562.
Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TME, Moffitt MS et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687–1697.
ACCORD Study Group and ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. New Engl J Med 2010; 363: 233–244.
Cushman WC, Evans GW, Byington RP, Goff Jr DC, Grimm Jr RH, Cutler JA et al. Effects of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575–1585.
Ginsberg HN, Elam MB, Lovato LC, Crouse 3rd JR, Leiter LA, Linz P et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563–1574.
Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L et al. Severe hypoglycaemia and risks of vascular events and death. N Engl J Med 2010; 363: 1410–1418.
Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–2572.
Enger C, Gately R, Ming EE, Niemcryk SJ, Williams L, McAfee AT . Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. Am J Cardiol 2010; 106: 1594–1601.
Hiukka A, Maranghi M, Matikaimen N, Taskinen M-R . PPARa: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol 2010; 5: 454–463.
Playford DA, Watts GF, Best JD, Burke V . Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. Am J Cardiol 2002; 90 (11): 1254–1257.
Israelian-Konaraki Z, Reaven PD . Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications. Cardiol Rev 2005; 13 (5): 240–246.
Tomizawa A, Hattori Y, Inoue T, Hattori S, Kasai K . Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase. Metabolism 2010 (E-pub ahead of print 25 June 2010; doi:10.1016/j.metabol.2010.04.020).
Kim J, Ahn J-H, Kim J-H, Yu Y-S, Kim H-S, Ha J et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res 2007; 84: 886–893.
Quresh M, Mark CG, Tien Y W . Management of diabetic retinopathy: a systematic review. JAMA 2007; 298 (8): 902–916.
White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP et al. Effect of Prior Intensive Therapy in Type 1 Diabetes on 10-Year Progression of Retinopathy in the DCCT/EDIC: Comparison of Adults and Adolescents. Diabetes 2010; 59: 1244–1253.
Klein BEK . Reduction in risk of progression of diabetic retinopathy. New Engl J Med 2010; 363: 287–288.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
ADW obtained consultative fee from Novartis and educational grant from Novo Nordisk, and PMD has served on advisory boards of Solvay, Takeda, and Novartis, and is principal investigator for the Protein Kinase C research programme for the UK.
Rights and permissions
About this article
Cite this article
Wright, A., Dodson, P. Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies. Eye 25, 843–849 (2011). https://doi.org/10.1038/eye.2011.62
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2011.62
Keywords
This article is cited by
-
Cholesterol crystal formation is a unifying pathogenic mechanism in the development of diabetic retinopathy
Diabetologia (2023)
-
Current epidemiology of diabetic retinopathy in patients with type 1 diabetes: a national multicenter study in Brazil
BMC Public Health (2018)
-
Incidence of diabetes retinopathy and determinants of time to diabetes retinopathy among diabetes patients at Tikur Anbessa Hospital, Ethiopia: a retrospective follow up study
BMC Research Notes (2018)
-
Palmitic Acid Induces Müller Cell Inflammation that is Potentiated by Co-treatment with Glucose
Scientific Reports (2018)
-
Abnormal islet sphingolipid metabolism in type 1 diabetes
Diabetologia (2018)
